Tag: Best Pharmaceutical Science Award

Shivani Chib | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Shivani Chib — Central University of Punjab

Shivani Chib
Affiliation Central University of Punjab
Country India
Scopus ID 57946271800
Documents 24
Citations 315
h-index 10
Subject Area Pharmaceutical Science
Event World Science Awards
Google Scholar ID 8hFOqyEAAAAJ

Shivani Chib is a researcher affiliated with the Central University of Punjab, India, whose stated subject area is Pharmaceutical Science. Available bibliographic information identifies 24 documents, 315 citations, and an h-index of 10 in the supplied Scopus profile. These indicators provide a quantitative overview of the research record represented in the cited author profile. [1]

This academic recognition page presents the research profile in the context of the Young Scientist Award associated with the World Science Awards. The article is intended as a structured scholarly summary and distinguishes bibliographic indicators from broader qualitative considerations of research contribution and relevance. [3]

Abstract

Shivani Chib is associated with the Central University of Punjab and works within the broad field of Pharmaceutical Science. The supplied bibliometric record reports 24 documents, 315 citations, and an h-index of 10. [1] These measures can be used to describe the documented visibility and citation history of the research output represented by the identified Scopus author profile. The researcher is considered in relation to the Young Scientist Award under the World Science Awards, with the available information supporting an assessment based on research activity, scholarly output, and bibliometric indicators. [3]

Keywords

  • Young Scientist Award
  • Shivani Chib
  • Pharmaceutical Science
  • Pharmaceutical Research
  • Bibliometrics
  • Research Impact
  • Central University of Punjab
  • World Science Awards

Introduction

Pharmaceutical Science encompasses interdisciplinary research concerned with the discovery, development, formulation, evaluation, and application of pharmaceutical products and related technologies. Researchers working in this field contribute to the scientific evidence base that supports advances in medicines, drug delivery, pharmaceutical analysis, and associated areas of biomedical research.

Within this broader academic context, Shivani Chib is identified with the Central University of Punjab in India. The supplied research record indicates a body of 24 documents and a citation count of 315, alongside an h-index of 10. [1] Such indicators are useful for describing publication and citation activity, although they do not independently establish the quality, originality, or practical significance of individual research contributions.

Research Profile

The available profile information places Shivani Chib within Pharmaceutical Science and identifies the Central University of Punjab as the institutional affiliation. The Scopus author identifier supplied for the researcher is 57946271800. [1] The corresponding Google Scholar identifier is 8hFOqyEAAAAJ, providing an additional route for locating scholarly material associated with the researcher. [2]

Bibliometric indicators should be interpreted in relation to publication age, disciplinary citation practices, authorship patterns, journal characteristics, and the nature of the research questions addressed. Consequently, the reported values are best treated as descriptive indicators rather than as a complete evaluation of scientific merit.

Research Contributions

The supplied information identifies Pharmaceutical Science as Shivani Chib’s principal subject area. On the basis of the available bibliographic record, the research profile can be considered within the wider pharmaceutical research ecosystem, where scholarly contributions may involve experimental investigation, pharmaceutical development, analytical approaches, formulation research, or related interdisciplinary work. Specific research contributions should be assessed from individual publications and their associated abstracts, methods, results, and citation contexts rather than inferred solely from aggregate metrics.

These elements provide a concise quantitative and institutional description of the research profile. A complete scholarly evaluation would additionally consider the originality of individual studies, methodological rigor, reproducibility, collaboration, research relevance, and contributions to scientific knowledge.

Publications

The supplied Scopus information reports 24 documents associated with Shivani Chib’s author profile. [1] Because individual publication titles, journal names, publication years, article types, and DOI identifiers were not provided in the source information supplied for this article, this section does not assign specific publications or DOI records to the researcher without verification.

The complete publication record can be consulted through the researcher’s Scopus author profile and Google Scholar profile. These databases can provide publication-level information, citation records, author associations, and other bibliographic details. [1] [2]

Research Impact

The supplied bibliometric record reports 315 citations across 24 documents, producing an average of approximately 13.1 citations per document when calculated from the provided values. The reported h-index of 10 indicates that, within the cited record, at least ten publications have each received at least ten citations under the applicable indexing and counting conditions. [1]

Citation indicators can help describe scholarly visibility but should not be treated as standalone measures of research quality or societal impact. Citation patterns vary substantially among disciplines and publication types. A broader assessment of impact may include scientific influence, methodological contributions, collaboration, translation into practice, educational value, and relevance to pharmaceutical research.

Award Suitability

The Young Scientist Award associated with the World Science Awards provides a recognition framework in which research activity, scholarly contributions, academic development, and evidence of research influence may be considered. [3] Based on the supplied information, Shivani Chib has a documented research profile in Pharmaceutical Science, an institutional affiliation with the Central University of Punjab, 24 reported documents, 315 citations, and an h-index of 10. [1]

These characteristics provide a reasonable bibliometric basis for consideration within an early-career or young-scientist recognition context. Final award suitability, however, should be determined using the official award criteria and a complete evaluation of the researcher’s publications, originality, scientific contribution, academic trajectory, and supporting documentation rather than bibliometric indicators alone. [3]

  1. Verified bibliographic and citation information should be considered from the relevant scholarly databases.
  2. Individual publications should be reviewed for originality, methodological quality, and contribution to Pharmaceutical Science.
  3. The official World Science Awards criteria should be used for the final award assessment.

Conclusion

Shivani Chib is a Pharmaceutical Science researcher affiliated with the Central University of Punjab, India. The supplied Scopus record identifies 24 documents, 315 citations, and an h-index of 10, providing a measurable overview of the research activity represented by the profile. [1] The available information supports consideration of the researcher in connection with the Young Scientist Award, while a comprehensive award decision should incorporate publication-level evidence and the official evaluation criteria of the World Science Awards. [3]

References

    1. Elsevier. (n.d.). Scopus author details: Shivani Chib, Author ID 57946271800. Scopus.
      https://www.scopus.com/pages/authors/57946271800

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Yongpan An | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Yongpan An | Pharmaceutical Science | Best Researcher Award

Pharmacology Researcher from Xi’an People’s Hospital (Xi’an Fourth Hospital), China

Yongpan An is an emerging researcher in the field of pharmacology, specializing in drug screening and the mechanistic study of aging and aging-related diseases. A recent Ph.D. graduate from Peking University, Dr. An has demonstrated significant promise through his contributions to high-impact research, authoring and co-authoring several peer-reviewed publications. His work spans various disciplines, including molecular biology, artificial intelligence, and pharmacological intervention, reflecting a multidisciplinary approach essential for innovative biomedical research. As of now, he is affiliated with Xi’an People’s Hospital, where he continues to build on his doctoral research. Dr. An has already co-authored influential studies published in journals such as Nature Biotechnology, Aging Cell, Frontiers in Pharmacology, and Life Medicine. Despite being early in his career, his scientific output, collaboration with renowned researchers, and peer review responsibilities signal a strong foundation for a successful academic trajectory. His research addresses a critical area in medical science—aging—and aims to identify compounds that can prolong lifespan and reduce age-associated degeneration. With demonstrated leadership in co-authorship roles and contributions to the understanding of pharmacological interventions for aging, Yongpan An stands out as a dedicated, capable, and innovative young scientist poised for further accomplishments.

Professional Profile

Education

Yongpan An’s academic journey reflects a solid foundation in biotechnology and pharmacology, cultivated through rigorous training at leading Chinese institutions. He began his undergraduate studies in Biotechnology at Yunnan University, where he developed fundamental skills in molecular biology and biochemical research. From 2014 to 2018, he was immersed in coursework and research that exposed him to laboratory techniques and foundational knowledge in life sciences. His pursuit of advanced studies led him to Peking University, one of China’s most prestigious academic institutions, where he obtained his Ph.D. in Pharmacology between 2018 and 2023. At Peking University, under the mentorship of Dr. Zhengwei Xie, he focused on drug screening and the molecular mechanisms underlying aging. During this period, Dr. An gained hands-on experience with advanced pharmacological methodologies, contributing to several high-impact studies. His doctoral training not only equipped him with scientific expertise but also fostered skills in critical thinking, interdisciplinary collaboration, and scientific communication. His research incorporated cutting-edge areas such as the application of artificial intelligence in drug discovery, reinforcing the modern relevance of his education. This academic progression—from biotechnology to pharmacology—provides a robust framework for his current and future research endeavors in aging and age-related diseases.

Professional Experience

Dr. Yongpan An is currently employed at Xi’an People’s Hospital, where he continues to engage in pharmacological research with a focus on aging and age-related diseases. Although early in his professional career, Dr. An has already demonstrated remarkable productivity and leadership in scientific research. During his doctoral studies at Peking University, he was deeply involved in collaborative projects that combined pharmacological experimentation with computational analysis. His work involved both in vivo and in vitro models, providing him with experience across various experimental platforms. In addition to research responsibilities, Dr. An served as a reviewer for the journal Pharmacological Research, evaluating scientific manuscripts and gaining familiarity with the editorial and peer-review process. His professional engagements have also included active participation in scientific conferences and forums, where he presented his findings and interacted with experts in the field of aging and pharmacology. Notably, he played a major role in authoring a comprehensive review titled The Landscape of Aging, where he was responsible for summarizing the application of artificial intelligence in anti-aging drug discovery. As he transitions from a student to an independent researcher, Dr. An continues to demonstrate commitment to excellence, innovation, and scientific rigor in his ongoing professional endeavors.

Research Interests

Dr. Yongpan An’s primary research interests lie in the pharmacological modulation of aging and the discovery of novel compounds targeting aging-related diseases. His work integrates drug screening techniques with the mechanistic study of cellular and organismal aging processes. Specifically, he is interested in understanding how small molecules interact with key molecular pathways, such as the AKT signaling cascade, p16, and cyclin regulatory mechanisms, to delay senescence and promote healthy lifespan extension. Another key area of interest for Dr. An is the use of natural products, such as oridonin and berberine, in regulating cellular aging. His contributions to this field are evident from his publications in high-impact journals that explore the therapeutic potential of such compounds in mouse and yeast models. Additionally, he has contributed to the development of AI-driven tools for predicting drug efficacy from transcriptional profiles, showcasing his interest in computational pharmacology. The integration of artificial intelligence and deep learning with experimental pharmacology highlights his vision of combining traditional experimental approaches with cutting-edge digital methodologies. His overarching goal is to discover and validate compounds that not only extend lifespan but also improve quality of life by mitigating the effects of chronic and degenerative diseases associated with aging.

Research Skills

Dr. Yongpan An possesses a diverse and interdisciplinary set of research skills, developed through years of academic training and hands-on laboratory experience. He is proficient in a wide range of pharmacological and molecular biology techniques, including cell culture, Western blotting, immunofluorescence, RNA extraction, and quantitative PCR. He has extensive experience working with animal models, especially in the context of lifespan and senescence studies in mice and yeast, which are central to his research in aging. His capabilities also include the screening and identification of bioactive compounds using high-throughput methods, allowing him to evaluate the pharmacodynamic and pharmacokinetic properties of candidate molecules. Dr. An is adept at using bioinformatics and artificial intelligence tools to analyze gene expression data and predict drug responses. This skillset was crucial in his involvement in the development of deep learning models for drug efficacy prediction, published in Nature Biotechnology. Moreover, his experience as a peer reviewer reflects his ability to critically assess scientific literature and evaluate experimental design, data quality, and interpretation. His collaborative skills and familiarity with interdisciplinary projects further enhance his research capabilities, making him an asset to both academic and clinical research teams focusing on anti-aging pharmacological interventions.

Awards and Honors

Despite being at the beginning of his career, Dr. Yongpan An has already received several prestigious awards in recognition of his academic excellence and research achievements. During his doctoral studies at Peking University, he was honored with the National Scholarship, a highly competitive award given to outstanding students in China. He also received the First Prize in the Soaring Young Scholar competition held by Northwestern Polytechnical University, which recognizes young researchers for innovative scientific contributions. Additionally, he was awarded the Second Prize at the Young Scientist Forum Report organized by the Beijing Society of Pharmacology and Physiological Sciences, affirming his potential as a promising figure in pharmacological research. These honors not only reflect his dedication to scientific inquiry but also underscore the impact and relevance of his work within the research community. His involvement as a co-first author in significant collaborative publications further demonstrates peer recognition of his scholarly efforts. Beyond awards, his service as a manuscript reviewer for an established journal like Pharmacological Research highlights the trust placed in his scientific judgment. Collectively, these accolades validate Dr. An’s emerging role as a capable and committed young scientist with a promising future in pharmacology and aging research.

Conclusion

In summary, Dr. Yongpan An embodies the qualities of a highly promising early-career researcher with a strong academic foundation, impactful research output, and growing recognition within the scientific community. His work focuses on one of the most critical areas in medical science—understanding and intervening in the aging process to improve human health and longevity. His background in both experimental pharmacology and artificial intelligence places him at the intersection of innovation and translational medicine. Despite his relatively recent graduation, he has already authored multiple first-author publications, participated in high-level collaborative research, and received awards for his contributions. Dr. An’s dedication to advancing the pharmacological understanding of aging-related diseases and his proactive engagement in academic publishing and peer review highlight his scientific maturity. He is currently well-positioned to expand his research, attract future funding, and lead independent projects that will further enhance his professional profile. As he continues to build his research portfolio at Xi’an People’s Hospital, Dr. An is likely to contribute significantly to the development of therapeutic strategies that target aging and its associated disorders. Therefore, he represents an outstanding candidate for recognition through awards that honor excellence in scientific research.

Publications Top Notes

  1. Title: Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
    Authors: Gao, Ke; Xi, Wenjin; Ni, Jianxin; Zhang, Rui; Wu, Guojun
    Journal: Biomaterials
    Year: 2025

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Radhika Khanna | Medicinal Chemistry | Best Researcher Award

Published on by World Science Awards

Ms. Radhika Khanna | Medicinal Chemistry | Best Researcher Award

Researcher at Forest Research Institute, India

Radhika Khanna is a dedicated researcher pursuing her Ph.D. at the Forest Research Institute (FRI), Dehradun. With a strong foundation in chemistry and years of experience in advanced analytical techniques, she has carved a niche in the fields of chemical characterization, conservation, and natural product research. Radhika has actively contributed to both academia and applied research, with multiple publications, including in high-impact journals such as the Journal of Ethnopharmacology. She holds a patent for a formulation addressing diabetes management, reflecting her commitment to creating solutions with societal relevance. Her participation in numerous national and international conferences, including the Young Scientist Conference (IISF 2023), underscores her engagement with the global scientific community. Radhika’s technical acumen in spectroscopy, chromatography, and her ability to leverage computational tools enhance her innovative research efforts.

Professional Profile

Education

Radhika Khanna’s educational journey demonstrates consistency and academic excellence. She completed her secondary education at Shri Ram Ashram Public School, Amritsar, achieving a commendable CGPA of 8.4. She then pursued her higher secondary education at Bhavans SL Public School, Amritsar, scoring 84%. For her undergraduate studies, she earned a B.Sc. in Medical Science from S.R. Government College, Amritsar, with a percentage of 65.75%. She went on to complete her M.Sc. in Chemistry at Khalsa College, Amritsar, graduating with an impressive 75%. Currently, Radhika is pursuing her Ph.D. at the prestigious Forest Research Institute (FRI), Dehradun, where her research focuses on the chemical characterization of forest genetic resources and natural product development.

Professional Experience

Radhika Khanna has garnered diverse research experience through impactful projects and academic roles. She initiated her research career during her postgraduate studies with a project on the design and synthesis of Schiff base-based chemosensors under the guidance of Dr. Kuljit Kaur at Khalsa College, Amritsar. This project honed her skills in advanced chemical synthesis and analysis. Currently, as a Ph.D. scholar at the Forest Research Institute, Dehradun, she is involved in the chemical characterization of forest genetic resources, guided by Dr. V.K. Varshney. These experiences have equipped her with expertise in analytical techniques, conservation strategies, and natural product research. Her active participation in international conferences further reflects her professional commitment to knowledge sharing and collaboration.

Research Interest

Radhika’s research interests lie in the fields of analytical chemistry, natural product development, and conservation science. She is passionate about exploring the chemical properties of forest genetic resources to unlock their potential for pharmaceutical and environmental applications. Her work focuses on the design and synthesis of chemosensors, which have significant applications in chemical detection and environmental monitoring. Additionally, she is deeply invested in the characterization of natural antioxidants and anti-inflammatory compounds, as demonstrated by her publications and patent on diabetes management. Radhika’s interdisciplinary research bridges analytical chemistry, pharmacology, and conservation, with the overarching goal of advancing sustainable and innovative solutions to global challenges.

Research Skills

Radhika Khanna possesses a robust skill set encompassing advanced analytical and computational techniques. Her expertise includes UV and IR spectroscopy, GCMS, HPLC, LCMS, column chromatography, and flash chromatography, which are vital for chemical analysis and natural product research. She is also proficient in software tools such as Corel Draw, Adobe Photoshop, and MS Office, as well as programming languages like C++ and HTML. These technical skills, combined with her proficiency in research methodologies, allow her to approach problems innovatively and efficiently. Furthermore, her hands-on experience in chemical synthesis, characterization, and conservation science underscores her capability to conduct interdisciplinary research.

Awards and Honors

Radhika Khanna’s dedication to research has earned her recognition at numerous national and international platforms. She has presented her work at prestigious events such as the Young Scientist Conference (IISF 2023) and the International Conference on Biodiversity & Bioprospecting in Kathmandu, Nepal. Her contributions to science have also been recognized at national conferences, including the Uttarakhand State Science and Technology Congress. Additionally, she has earned certifications in IT foundation programs and personality development, enhancing her holistic skillset. Her innovative research efforts are further highlighted by her patent for a formulation addressing diabetes management, cementing her reputation as a researcher committed to impactful and solution-driven science.

Conclusion

Radhika Khanna is a promising candidate for the Best Researcher Award based on her technical skills, active participation in the scientific community, and impactful research outputs such as a patent and publications. However, enhancing the specialization depth of her research, increasing her publication count, and gaining more diversified professional experience would solidify her position as a top contender. Given her strengths, Radhika is a worthy nominee, particularly in categories emphasizing innovation and technical expertise.

Publication Top Notes

  1. In vitro and in vivo anti-inflammatory activity of Cupressus torulosa D. DON needles extract and its chemical characterization
    • Authors: R Khanna, K Bhadoriya, YC Tripathi, VK Varshney
    • Year: 2023
    • Journal: Journal of Ethnopharmacology
    • Citations: 4
  2. Cupressus torulosa, a Source of Antioxidant Polyphenols: An Analytical and Pharmacological Study
    • Authors: R Khanna, HR Chitme, K Bhadoriya, VK Varshney
    • Year: 2025
    • Journal: Rapid Communications in Mass Spectrometry
  3. Toxicity studies, Hypoglycaemic activity of Cupressus torulosa needles and recognition of active molecules
    • Authors: R Khanna
    • Year: 2023
    • Journal: MDPI

 

 

 

Prem Shankar Mishra | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Prem Shankar Mishra | Pharmaceutical Science | Best Researcher Award

Professor at Galgotias University, India

Dr. Prem Shankar Mishra is a distinguished academician and pharmaceutical scientist currently serving as Associate Professor and Head of the D.Pharm Programme at Galgotias University. With over a decade of experience in teaching, research, and academic administration, he has established himself as a result-oriented educator and innovative researcher in pharmaceutical sciences. His expertise spans drug design, heterocyclic synthesis, molecular docking, anticancer research, and analytical characterization techniques. Dr. Mishra has successfully guided undergraduate and diploma pharmacy students while contributing significantly to curriculum development, accreditation processes, and outcome-based education systems. He has published numerous research articles in reputed international journals and authored book chapters with global publishers. In addition to his academic contributions, he holds multiple granted Indian and international patents in the fields of pharmaceutical formulations, synthetic chemistry, and biomedical devices. His leadership roles in NAAC/NBA accreditation activities and conference organization reflect his administrative competence and commitment to quality education. Dr. Mishra integrates research innovation with academic excellence, promoting interdisciplinary collaboration and fostering a culture of scientific inquiry. His professional journey reflects dedication to advancing pharmaceutical education and impactful drug discovery research.

Professional Profile

Education

Dr. Prem Shankar Mishra possesses a strong and multidisciplinary academic foundation in pharmacy and law. He completed his Ph.D. in Pharmacy from VISTAS in 2021, focusing on the design, synthesis, and evaluation of 2-pyridone derivatives as potential anticancer agents. His doctoral research emphasized drug design, heterocyclic synthesis, molecular docking, and in-vitro anticancer evaluation under expert supervision from NIPER Kolkata leadership. He earned his Master of Pharmacy (M.Pharm) in Pharmaceutical Chemistry from The Tamil Nadu Dr. M.G.R. Medical University in 2010, building strong expertise in synthetic chemistry and analytical techniques. Earlier, he completed his Bachelor of Pharmacy (B.Pharm) from an institution affiliated with Uttar Pradesh Technical University in 2007. Expanding his interdisciplinary knowledge, he also obtained a Bachelor of Laws (LL.B.) degree from Chaudhary Charan Singh University in 2017. His educational background combines pharmaceutical sciences, research methodology, regulatory awareness, and legal understanding, enabling him to contribute effectively to academic leadership, patent development, and regulatory compliance in higher education and pharmaceutical research.

Professional Experience

Dr. Prem Shankar Mishra has more than ten years of comprehensive experience in teaching, research supervision, and academic administration. Since December 2017, he has been serving as Associate Professor in the Department of Pharmacy at Galgotias University, where he also holds the position of Head of the D.Pharm Programme. In this role, he oversees curriculum implementation, faculty coordination, accreditation processes, regulatory compliance with PCI, NAAC, and NBA standards, and academic planning aligned with outcome-based education under the Washington Accord framework. Prior to this, he worked as Assistant Professor at Meerut Institute of Engineering and Technology from 2010 to 2017, contributing to undergraduate and postgraduate pharmacy education. He also gained early teaching experience as a guest lecturer at Government Polytechnic College, Lakhimpur Kheri. Beyond classroom teaching, Dr. Mishra has organized international conferences, participated in faculty development programs, and served as an external examiner for pharmacy institutions. His professional journey reflects consistent academic growth, leadership in quality assurance initiatives, student mentorship, and active engagement in research-driven pharmaceutical education and institutional development.

Research Interests

Dr. Prem Shankar Mishra’s research interests are centered on pharmaceutical chemistry with a strong emphasis on anticancer drug discovery and development. His primary focus includes the design, synthesis, and characterization of heterocyclic compounds, particularly 2-pyridone and pyridazine derivatives, for potential therapeutic applications. He actively integrates in-silico molecular docking studies with wet-lab synthesis and biological evaluation to accelerate rational drug design. His expertise extends to cell culture-based assays such as MTT assays, flow cytometry (FACS), cell cycle analysis, and reactive oxygen species studies for evaluating cytotoxic effects. Dr. Mishra is also interested in green synthesis approaches, nano-formulations, transdermal delivery systems, and advanced analytical techniques including IR, NMR, HPLC, and UV spectroscopy. He has contributed to computational drug discovery, deep learning applications in site-specific drug delivery, and immunotherapy-based strategies targeting skin cancer. His interdisciplinary research approach bridges synthetic organic chemistry, computational modeling, pharmacological screening, and formulation science. Through funded proposals and patented innovations, he continues to explore novel bioactive molecules and advanced drug delivery systems aimed at improving therapeutic efficacy and safety.

Awards and Honors

Dr. Prem Shankar Mishra has received notable recognition for his academic and research contributions in pharmaceutical sciences. He has secured multiple granted Indian and international patents, including innovations in nanoemulgel formulations, pyridazine derivatives, antimicrobial devices, and transdermal drug delivery systems. His research initiatives have attracted funding support, including a grant from DRDO for organizing a national conference, reflecting institutional trust in his academic leadership. He has actively participated in national and international conferences, winning awards such as first prize in oral presentation during National Pharmacy Week. Dr. Mishra has completed several prestigious NPTEL-AICTE and AICTE-ATAL sponsored faculty development programs focusing on accreditation, patent creation, outcome-based education, and innovative pedagogy. His involvement as a core team member in NAAC/NBA accreditation processes highlights his commitment to maintaining academic quality standards. Additionally, he has served as an external examiner and evaluator for pharmacy institutions. These achievements demonstrate his dedication to academic excellence, research innovation, patent development, professional training, and continuous professional growth in pharmaceutical education and drug discovery research.

Conclusion

Dr. Prem Shankar Mishra exemplifies a balanced integration of academic excellence, innovative research, and effective leadership in pharmaceutical sciences. With strong qualifications in pharmacy and law, extensive teaching experience, and active engagement in drug discovery research, he has made meaningful contributions to anticancer therapeutics, molecular modeling, and pharmaceutical formulation development. His granted patents and funded research proposals reflect his commitment to translational research and practical innovation. As an academic leader at Galgotias University, he plays a vital role in curriculum development, accreditation processes, and outcome-based education implementation. His ability to combine computational drug design, synthetic chemistry, biological evaluation, and regulatory understanding demonstrates interdisciplinary strength. Through mentorship, research publications, conference organization, and policy contributions, he continues to foster scientific inquiry and academic quality. Dr. Mishra’s career trajectory highlights sustained dedication to advancing pharmaceutical education, strengthening research culture, and contributing to impactful drug development strategies aimed at addressing critical healthcare challenges.

Publication Top Noted

  1. Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential
    Year: 2025
    📝 Contributors: Megha Verma, Prem Shankar Mishra, S.K. Abdul Rahaman, Tanya Gupta, Abid Ali Sheikh, Ashok Kumar Sah, and international collaborators
    📚 Journal: Biomedicines
    📌 Type: Review • Open Access
    📊 Citations: 1
  2. Implementation of QKD-Based System Using Nano PCF for Healthcare Applications
    Year: 2025
    Contributors: A.K. Vyas, A. Dixit, S. Tiwari, Prem Shankar Mishra, D.K. Gupta, S. Srivastava, V. Singh
    Journal: Sensing and Bio-Sensing Research
  3. AI-Assisted Immunology for Precision Cancer Medicine
    Year: 2025
    Contributors: Ashok Kumar Sah, Megha Verma, Prem Shankar Mishra, S.K. Abdul Rahaman, Tanya Gupta, and co-authors
    Citations: 1

Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Published on by World Science Awards

Assist Prof Dr. Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Assistant Professor, EDA, Egypt

With a solid foundation in pharmacy, including a Bachelor’s, Master’s, and PhD from Cairo University, and a position as Associate Professor, this individual demonstrates exceptional expertise. Their diverse professional experience spans quality control, management, and academic roles, showcasing their leadership and practical knowledge in the pharmaceutical field. Their prolific research output includes numerous publications on advanced drug delivery systems and nanotechnology, reflecting significant contributions to pharmaceutical sciences. Active participation in various training courses, workshops, and international conferences highlights their commitment to continuous professional development. Additionally, their multilingual skills enhance their ability to collaborate in diverse settings. Overall, their comprehensive background in education, research, and professional development, combined with their active engagement in the scientific community, makes them a highly suitable candidate for the Best Researcher Award.

Education

The candidate has a robust educational background that serves as the foundation of their expertise in the field of pharmaceutical sciences. They earned a Bachelor of Pharmacy degree from Cairo University in 1996, graduating with honors, which set the stage for their academic and professional journey. Their pursuit of advanced knowledge led them to complete a Master’s degree in Pharmaceutics in 2007 and later a PhD in 2011, both from the same esteemed institution. This rigorous academic training has equipped them with in-depth knowledge of pharmaceutics, drug formulation, and pharmaceutical analysis. In 2019, they further solidified their academic credentials by attaining the position of Associate Professor, demonstrating their commitment to education, research, and mentorship. Their continuous academic progression reflects a strong commitment to excellence and a desire to contribute significantly to the pharmaceutical sciences, positioning them as a thought leader in their field and a prime candidate for the Best Researcher Award.

Profesional Experience

The candidate has an extensive professional background in the pharmaceutical sector, beginning their career as a QC analyst for raw materials at NODCAR from 1996 to 1999. They then transitioned to academia as a teaching assistant at the Faculty of Pharmacy, October University, in 1999. Between 2000 and 2012, they worked as a QC analyst specializing in physical properties before moving into management roles, including quality manager and deputy lab manager. From 2016 to 2021, they served as a technical manager, demonstrating their expertise in overseeing laboratory operations and maintaining quality standards. Their role expanded further as they joined several committees, contributing to updating pharmaceutical guidelines and developing the Egyptian pharmacopeia. In 2021, they became the lab manager of the physicochemical lab at the Egyptian Drug Authority (EDA), where they continue to lead and innovate in quality control and research.

Research Skill

The candidate possesses exceptional research skills, demonstrated through a prolific publication record in high-impact journals and extensive experience in developing innovative pharmaceutical formulations. They have expertise in designing and conducting complex experimental studies, including the use of advanced methodologies like Box–Behnken design for optimization and in vivo evaluations. Their research work spans various domains, including nanotechnology, ocular drug delivery, and gastroretentive systems, showcasing versatility and a strong ability to adapt to emerging scientific trends. Additionally, their role in supervising master’s and PhD theses highlights their leadership in guiding future researchers. The candidate is also well-versed in utilizing statistical analysis tools and quality-by-design approaches, which are critical for ensuring the rigor and reliability of research findings. Their ability to translate research into practical applications, coupled with active participation in committees that shape pharmaceutical guidelines, underscores a profound impact on both academic and industry standards in the pharmaceutical sciences.

Awards And Recoginition

The individual has received multiple accolades throughout their career, reflecting their outstanding contributions to the field of pharmaceutical sciences. Their expertise in pharmaceutics and dedication to research have been recognized by esteemed institutions and professional bodies. Notably, they have been honored for their innovative work in drug delivery systems and quality management, which have had a significant impact on the pharmaceutical industry. They have been a valuable member of committees responsible for updating pharmaceutical guidelines and establishing national standards, further highlighting their influence and leadership in the field. Additionally, their research publications in renowned international journals have been widely cited, earning them recognition among peers as a leading researcher. Their participation in prestigious conferences and workshops, both as a presenter and a participant, underscores their commitment to continuous learning and sharing knowledge. These recognitions affirm their position as a distinguished professional dedicated to advancing pharmaceutical science and improving healthcare outcomes.

Conclution

The individual’s blend of academic excellence, practical experience, prolific research output, and continuous professional growth makes them a highly suitable candidate for the Best Researcher Award. Their achievements reflect their dedication to advancing pharmaceutical science and their impact on the field.

Publication Top Notes

  1. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency
    • Authors: Nagham H. Kamal, Fatema R. Saber, Abeer Salama, Dalia M. N. Abouhussein, Soha Ismail, Hala M. El-Hefnawy, Meselhy R. Meselhy
    • Year: 2024
    • Citation: Kamal NH, Saber FR, Salama A, Abouhussein DMN, Ismail S, El-Hefnawy HM, Meselhy MR. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency. Future Journal of Pharmaceutical Sciences. 2024 Aug 19. doi:10.1186/s43094-024-00678-2.
  2. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment
    • Authors: Abeer Khattab, Soha Ismail, Areeg M. Abd-Elrazek
    • Year: 2024
    • Citation: Khattab A, Ismail S, Abd-Elrazek AM. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment. AAPS PharmSciTech. 2024 Jun 27. doi:10.1208/s12249-024-02852-4.
  3. Optimization of topical curcumin spanlastics for melanoma treatment
    • Authors: Soha Ismail, Doaa Garhy, Howida K. Ibrahim
    • Year: 2023
    • Citation: Ismail S, Garhy D, Ibrahim HK. Optimization of topical curcumin spanlastics for melanoma treatment. Pharmaceutical Development and Technology. 2023 May 28. doi:10.1080/10837450.2023.2204926.
  4. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation
    • Authors: Marwa H. Shukr, Soha Ismail, Ghada G. El-Hossary, Amany H. El-Shazly
    • Year: 2022
    • Citation: Shukr MH, Ismail S, El-Hossary GG, El-Shazly AH. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation. Journal of Liposome Research. 2022 Oct 2. doi:10.1080/08982104.2022.2025828.
  5. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI
    • Authors: Marwa Farrag Abd El-Aziz, Soha Ismail, Mina Ibrahim Tadros, Mohamed Ahmed Elnabarawi
    • Year: 2020
    • Citation: Abd El-Aziz MF, Ismail S, Tadros MI, Elnabarawi MA. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI. Pharmaceutical Development and Technology. 2020 May 27. doi:10.1080/10837450.2020.1720235.
  6. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity
    • Authors: Marwa H. Shukr, Soha Ismail, Samya Mahmoud Ahmed
    • Year: 2019
    • Citation: Shukr MH, Ismail S, Ahmed SM. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity. Journal of Drug Delivery Science and Technology. 2019 Feb. doi:10.1016/j.jddst.2018.12.001.
  7. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy
    • Authors: Dalia S. Shaker, Soha Ismail, Selwan Hamed, Eman M. El-Shishtawy
    • Year: 2018
    • Citation: Shaker DS, Ismail S, Hamed S, El-Shishtawy EM. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy. Journal of Drug Delivery Science and Technology. 2018 Dec. doi:10.1016/j.jddst.2018.09

 

Xian Zheng | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Xian Zheng | Pharmaceutical Science | Best Researcher Award

Assistant research Fellow of Affiliated Kunshan Hospital of Jiangsu University, China.

Xian Zheng is a prominent researcher specializing in Chinese herbal drugs, natural products, and nonalcoholic fatty liver disease (NAFLD). With a Ph.D. in Chinese pharmacy from China Pharmaceutical University, he currently serves as an Assistant Researcher at the Affiliated Kunshan Hospital of Jiangsu University and a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics. Zheng leads several high-impact projects, including studies on arjunolic acid and liposome-based therapies for NAFLD, supported by major funding bodies like the National Natural Science Foundation of China. His research is well-regarded, with numerous publications in leading journals such as Phytomedicine and J Functional Foods. Zheng has been honored with awards like Jiangsu Double Innovation Doctor and Gusu Health Talents Plan-“Class D special talents”. His work showcases significant contributions to the field, marked by a strong publication record and leadership in innovative research.

Profile
Education

Xian Zheng’s educational background reflects a strong foundation in pharmacology and pharmacy. He earned his Ph.D. in Chinese Pharmacy from the College of Traditional Chinese Medicine at China Pharmaceutical University, Nanjing, in December 2021, under the supervision of Professor Zhiqi Yin. Prior to this, he completed his Master of Science in Pharmacology at the School of Pharmacy, Xuzhou Medical University, in June 2018, guided by Professor Yi Liu. Zheng’s academic journey began with a Ph.D. in Pharmacy from the School of Pharmacy, Nanjing2 University of Chinese Medicine, which he completed in June 2015. This extensive education, encompassing both traditional Chinese medicine and modern pharmacology, has provided him with a robust understanding of drug development and therapeutic applications, particularly in the realm of natural products and their effects on nonalcoholic fatty liver disease.

Professional Experience

Xian Zheng currently serves as an Assistant Researcher at the Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, where he has been contributing to cutting-edge research since February 2022. Additionally, he is a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics, a position he has held since October 2022. Zheng’s professional journey includes significant achievements in studying Chinese herbal drugs and natural products, particularly in the context of nonalcoholic fatty liver disease (NAFLD). He leads multiple high-profile research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Gusu Health Talent Research Project. His expertise in pharmacology and his leadership in these research initiatives highlight his dedication and impact in advancing therapeutic strategies for NAFLD and related conditions.

Research Interest

Xian Zheng’s research interests primarily focus on Chinese herbal drugs and natural products, with a particular emphasis on their therapeutic potential for nonalcoholic fatty liver disease (NAFLD). His work explores innovative treatment approaches, such as the dual NAMPT activation theory, and the development of liposome-based drug delivery systems to enhance the efficacy of herbal compounds. Zheng’s research aims to uncover the underlying mechanisms of these treatments, such as their effects on metabolic pathways and cellular functions. He is dedicated to advancing the understanding of how traditional herbal remedies can be optimized and integrated into modern therapeutic strategies for complex liver diseases. By combining traditional pharmacological insights with contemporary biomedical techniques, Zheng seeks to bridge the gap between ancient remedies and modern medicine, ultimately improving clinical outcomes for patients with NAFLD and contributing to the broader field of natural product research.

Research Skills

Xian Zheng demonstrates exceptional research skills, particularly in the domain of pharmacology and natural product research. His expertise encompasses a comprehensive understanding of Chinese herbal drugs and their therapeutic applications, with a specific focus on nonalcoholic fatty liver disease (NAFLD). Zheng excels in designing and leading innovative research projects, such as exploring dual NAMPT activation and developing liposome-based therapies for NAFLD. His ability to secure funding from prestigious organizations, including the National Natural Science Foundation of China, underscores his proficiency in research proposal development and project management. Zheng’s analytical skills are evident in his extensive publication record in reputable journals, where he contributes to advancing knowledge in his field. His role as a part-time postdoctoral researcher further reflects his commitment to scientific inquiry and collaboration. Overall, Zheng’s research skills are marked by a blend of innovative thinking, effective project leadership, and a strong publication track record.

Awards and Recognition

Xian Zheng has earned notable recognition in his field through a series of prestigious awards and honors. His achievements include being named a Jiangsu Double Innovation Doctor, which acknowledges his exceptional contributions to innovative research in Chinese pharmacy. Additionally, Zheng is distinguished as a “Class D special talents” under the Gusu Health Talents Plan, underscoring his impactful work in the realm of natural products and nonalcoholic fatty liver disease. He was also recognized as a Kunshan Youth Post Expert in 2022 and a Suzhou Youth Post Expert in 2023, highlighting his significant contributions to the scientific community and his leadership in advancing research. These accolades reflect Zheng’s dedication and impact in the field of pharmacology and his commitment to advancing therapeutic approaches through his innovative research efforts.

Conclusion

Dr. Tao Song is a strong candidate for the Best Researcher Award due to his significant contributions to the field of catalysis and green chemistry. His innovative research and high-impact publications demonstrate a clear potential for future leadership in the field. To further strengthen his candidacy, Dr. Song could focus on expanding the impact of his research through interdisciplinary collaborations and leadership roles. Given his achievements and potential, Dr. Song is well-suited for recognition as a leading researcher in his field.

Publications Top Notes

  1. Arjunolic Acid from Cyclocarya paliurus Selectively Inhibits Glucagon Secretion from α Cells and Ameliorates Diabetes via Ephrin-A1 and EphA4 Interaction
    • Authors: Fang, C.-Q., Teng, Y., Wang, Y.-T., Cao, X.-L., Jiang, C.-H.
    • Year: 2022
  2. Aloin A Prevents Ulcerative Colitis in Mice by Enhancing the Intestinal Barrier Function via Suppressing the Notch Signaling Pathway
    • Authors: Jiang, H., Shi, G.-F., Fang, Y.-X., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 11
  3. Protective Effects of Cyclocarya paliurus on Hyperuricemia and Urate-Induced Inflammation
    • Authors: Zhu, L.-H., Xu, Y.-Y., Zhu, L.-P., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 9
  4. Cyclocarya paliurus Triterpenoids Attenuate Glomerular Endothelial Injury in Diabetic Rats via ROCK Pathway
    • Authors: Yang, R., Xu, S., Zhang, X., Yin, Z., Pan, K.
    • Year: 2022
    • Citations: 8
  5. Chrysin Inhibits Hepatocellular Carcinoma Progression Through Suppressing Programmed Death Ligand 1 Expression
    • Authors: Rong, W., Wan, N., Zheng, X., Gao, Z.-J., Zhang, J.
    • Year: 2022
    • Citations: 17
  6. New Dammarane-Type Triterpenoid Saponins from Gynostemma pentaphyllum and Their Sirt1 Agonist Activity
    • Authors: Lou, Y.-Y., Zheng, X., Huang, Y.-P., Yin, Z.-Q., Pan, K.
    • Year: 2021
    • Citations: 12
  7. Arjunolic Acid from Cyclocarya paliurus Ameliorates Nonalcoholic Fatty Liver Disease in Mice via Activating Sirt1/AMPK, Triggering Autophagy and Improving Gut Barrier Function
    • Authors: Zheng, X., Zhang, X.-G., Liu, Y., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 6
  8. Aloe Vera Mitigates Dextran Sulfate Sodium-Induced Rat Ulcerative Colitis by Potentiating Colon Mucus Barrier
    • Authors: Shi, G., Jiang, H., Feng, J., Jiang, C., Zhang, J.
    • Year: 2021
    • Citations: 30
  9. Four New Dammarane Triterpenoid Glycosides from the Leaves of Cyclocarya paliurus and Their SIRT1 Activation Activities
    • Authors: Zhu, L.-P., Yang, H.-M., Zheng, X., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 7
  10. Gypenoside LVI Improves Hepatic LDL Uptake by Decreasing PCSK9 and Upregulating LDLR Expression
    • Authors: Wang, J., Wang, Y.-S., Huang, Y.-P., Yin, Z.-Q., Zhang, J.
    • Year: 2021
    • Citations: 21